Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com
Novel Biomarkers May Inform Prognosis in SCLC

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com
Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center
ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com
5 Key FDA Approval Dates Mark a Milestone-Filled May

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

AJMC® in the Press, January 5, 2018
January 5th 2018

AJMC® in the Press, January 5, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Bo Gamble on COA's Role in 2018
January 5th 2018

Bo Gamble on COA's Role in 2018

Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), believes that broadening communication and education is COA’s main goal in 2018.
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 4th 2018

Judy Berger on What Southwest Airlines Is Doing in Oncology

Southwest Airlines has set up a split fill program, pharmacy benefit manager, health advocacy program, and a cancer resource guide for employees, said Judy Berger, senior manager, benefits planning, Southwest Airlines.
Judge Dismisses Challenge to 340B Cuts, Final Rule Goes Into Effect
January 4th 2018

Judge Dismisses Challenge to 340B Cuts, Final Rule Goes Into Effect

Jaime Rosenberg
A federal judge dismissed a move to block 340B cuts days before CMS’ final rule on it went into effect.
Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib
January 4th 2018

Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib

Jaime Rosenberg
Carfilzomib was associated with higher rates of all-grade and high-grade cardiovascular adverse events (CVAE), and both later trial phase and higher doses of carfilzomib were associated with higher rates of CVAE, according to a study in JAMA Oncology.
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
January 3rd 2018

Terrill Jordan Discusses Making Refinements in Year 2 of OCM

Year 2 of the Oncology Care Model is about learning from the lessons of year 1 and extending implementation that has already been started, said Terrill Jordan, CEO of Regional Cancer Care Associates.
Serum Protein Signature Predicts Survival in Patients With Melanoma Receiving Anti–PD-1 Therapy
January 3rd 2018

Serum Protein Signature Predicts Survival in Patients With Melanoma Receiving Anti–PD-1 Therapy

Jaime Rosenberg
A pre-treatment signature of proteins used to predict survival in patients with metastatic melanoma receiving PD-1 inhibitors found that patients deemed sensitive by the test demonstrated significantly better overall survival.
Site Logo
January 1st 2018

How Value Frameworks Define Durable Survival of New Immuno-Oncology Agents

Laura Joszt, MA
New immuno-oncology agents are providing durable survival for some patients, but the cost of these treatments is very high, which is a cause for concern. In a new study in JAMA Oncology, researchers sought to assess how value frameworks defined the efficacy of new immuno-oncology agents.
Smokers Willing to Try E-Cigarettes More Successful at Smoking Less, Study Says
December 31st 2017

Smokers Willing to Try E-Cigarettes More Successful at Smoking Less, Study Says

Allison Inserro
A small pilot study from the Hollings Cancer Center at the Medical University of South Carolina found that smokers who are willing to use e-cigarettes tend to smoke less and have increased quit attempts.
Site Logo
December 29th 2017

The Impact High OOP Costs Have on Patients Filling Prescriptions for Oral Cancer Drugs

Laura Joszt, MA
Patients with cancer may have more options for oral cancer medications, but high out-of-pocket costs still present a barrier to access, according to a new study in Journal of Clinical Oncology.
This Week in Managed Care: December 29, 2017
December 29th 2017

This Week in Managed Care: December 29, 2017

This week, the top managed care stories included a road map to develop state-level programs to care for complex populations; the Physician-focused Payment Technical Advisory Committee backed 2 new alternative payment models; a new cancer gene profiling test may open doors to new targeted therapies.
Top 2017 Articles in AJMC®'s Evidence-Based OncologyTM
December 29th 2017

Top 2017 Articles in AJMC®'s Evidence-Based OncologyTM

Surabhi Dangi-Garimella, PhD
A look at the most popular articles published in Evidence-Based Oncology™ in 2017.
Dr Amy Abernethy Discusses Community Oncologists' Role in Modernizing Evidence Generation
December 27th 2017

Dr Amy Abernethy Discusses Community Oncologists' Role in Modernizing Evidence Generation

Community oncologists have a major role in accelerating treatment development and providing them to patients, said Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies
December 27th 2017

Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies

Jaime Rosenberg
While FoundationOne CDx, the comprehensive companion diagnostic test for solid tumors, gives patients the ability to be accurately matched with a targeted therapy, it also has potential benefits for patients with a less common types of cancers, said Stuart Goldberg, MD, chief scientific officer, Cota, in an interview with The American Journal of Managed Care®.
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26th 2017

Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate

Until more data is available, it’s difficult for a practice or physician group to make an accurate assessment of whether or not 2-sided risk is appropriate, said Sarah Cevallos, chief revenue cycle officer, Florida Cancer Specialists. Physicians would need to see clear metrics in order to know if they will be achievable.
The Role of Oncologists in Moving to Value-Based Care: Torrie Fields Interviews Dr Michael Kolodziej
December 25th 2017

The Role of Oncologists in Moving to Value-Based Care: Torrie Fields Interviews Dr Michael Kolodziej

In this interview, recorded at the end of the first day of PCOC®, Torrie Fields, senior program manager at Blue Shield of California, and Michael Kolodziej, MD, of ADVI Health, discuss the move to value-based care in oncology, what practices need to do to be successful, and the role of team-based care.
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25th 2017

Dr Shannon Maude Discusses Side Effects of CAR T Therapies

Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
Podcast: This Week in Managed Care—Individual Mandate Eliminated and Other Health News
December 23rd 2017

Podcast: This Week in Managed Care—Individual Mandate Eliminated and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Dr Bobby Green on How Flatiron Is Working to Improve Care Delivery
December 23rd 2017

Dr Bobby Green on How Flatiron Is Working to Improve Care Delivery

Bobby Green, MD, MSCE, senior vice president of clinical oncology at Flatiron Health, discusses analyzing patient data to improve the overall care delivery and its challenges involved with being so early in the process.
This Week in Managed Care: December 22, 2017
December 22nd 2017

This Week in Managed Care: December 22, 2017

This week, the top managed care stories included the elimination of the Affordable Care Act's individual mandate; a new gene therapy for inherited vision loss that could cost $1 million; and a study found that social isolation can increase the risk of type 2 diabetes.
Site Logo
December 22nd 2017

Medical World News®, December 2017

AJMC Staff
Key drug approvals; alcohol cancer link.
Articles That Gained the Most Traction on Facebook, Twitter, and LinkedIn in 2017
December 22nd 2017

Articles That Gained the Most Traction on Facebook, Twitter, and LinkedIn in 2017

Jaime Rosenberg
Articles on type 2 diabetes management, colon cancer screenings, and anti-rheumatic drug approvals topped the list.
Terrill Jordan: Year 1 Feedback on OCM
December 22nd 2017

Terrill Jordan: Year 1 Feedback on OCM

Based on CMMI's year 1 feedback on OCM, it is clear that a lot of planning is needed and education is crucial, said Terrill Jordan, CEO, of Regional Cancer Care Associates.
5 Aspects of How Diet Does, and Does Not, Impact Health
December 22nd 2017

5 Aspects of How Diet Does, and Does Not, Impact Health

Laura Joszt, MA
For the most part, it’s well known that eating healthy and in moderation is more beneficial to our health. In 2017, there were a number of news stories that drove that knowledge home.
FDA Grants Approval to Pertuzumab for Adjuvant Treatment in Patients With HER2-Positive Breast Cancer
December 21st 2017

FDA Grants Approval to Pertuzumab for Adjuvant Treatment in Patients With HER2-Positive Breast Cancer

Jaime Rosenberg
The FDA's 2013 accelerated approval of pertuzumab for neoadjuvant use was converted to full approval as part of treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer.
Site Logo
December 20th 2017

Will 2-Sided Risk Be a Reality in the OCM?

Kelly Davio
Site Logo
December 20th 2017

AJMC®tv Interviews, December 2017

The Center for Biosimilars&reg Laura Joszt, MA
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
Insights From Top 5 AJMC.com Contributor Articles of 2017
December 20th 2017

Insights From Top 5 AJMC.com Contributor Articles of 2017

Allison Inserro
Contributors to AJMC.com delved into data to share their knowledge about important topics in managed care, and in 2017, these were the top 5 most-read articles they wrote and published on our online managed care network.
Nat Turner on Using Data for New Payment Model Requirements
December 20th 2017

Nat Turner on Using Data for New Payment Model Requirements

Nat Turner, co-founder and CEO of Flatiron Health, discusses how oncologists use data to assist them in meeting the requirements in new payment models.
Site Logo
December 20th 2017

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

Stanley E. Waintraub, MD Donna McNamara, MD Deena Mary Atieh Graham, MD Andrew L. Pecora, MD John Min, BS Tommy Wu, BA Hyun Gi Noh, MSC Jacqueline Connors, RN, OCN Ruth Pe Benito, MPH, BS Kelly Choi, MD Eric Schultz, BS Stuart L. Goldberg, MD
Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.
<1
...
596061626364656667
...
185>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo